First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

Haemophilia

Volumn 23, Issue 5, 2017, Pages 654-659

  Collins, P ^a   Chalmers, E ^b   Alamelu, J ^c   Hay, C ^d   Liesner, R ^e   Makris, M ^f   Mathias, M ^e   Payne, J ^g   Rangarajan, S ^h   Richards, M ⁱ   Talks, K ^j   Tunstall, O ^k   Williams, M ^l   Hart, D P ^m  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^c EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^d Haemophilia Centre   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^g SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^h BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

ⁱ Leeds Children's Hospital   (United Kingdom)

^j NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^l BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^m QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; CHILDHOOD DISEASE; CLINICAL PROTOCOL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; FOLLOW UP; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; CHILD; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY;

CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; UNITED KINGDOM;

EID: 85020101177     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13264     Document Type: Article

References (18)

1. Valentino LA, Kempton CL, Kruse-Jarres R, Mathew P, Meeks SL. Reiss UM; International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia. 2015;21:559-567.
2. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) A United Kingdom Haemophilia Centre Doctors' Organisation guideline approved by the British Committee for Standards in Haematology. Brit J Haematol. 2013;162:758-773.
3. Gringeri A, Mannucci PM. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia. 2005;11:611-619.
4. Hay CR, DiMichele DM. International Immune Tolerance Study: The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2011;119:1335-1344.
5. NHS England 2015. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/07/16042_FINAL.pdf. Accessed February 22, 2017.
6. Mariani G, Ghirardini A, Belloco R. Immunetolerance in hemophilia. Principal results from the international registry. Thromb Haemost. 1994;72:155-158.
7. Kroner BL. Comparison of the international immune tolerance registry and the North American Immune tolerance registry. Vox Sang. 1999;77:33-37.
8. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang. 1999;77(Suppl 1):31-32.
9. Mauser-Bunschoten EP, Niewenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood. 1995;86:983-988.
10. Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149:498-507.
11. Smith MP, Spence KJ, Waters EL, et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII antibodies: comprehensive analysis of experience at a single institution. Thromb Haemost. 1999;81:35-38.
12. Rocino A, de Biasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sang. 1999;81:35-38.
13. Nakar C, Manco-Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015;21:365-373.
14. Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia. 2010;2010:71-79.
15. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413-420.
16. Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;2008:1319-1326.
17. Blancette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in haemophilia: communication frm the SSC of ISTH. J Thromb Haemostasis. 2014;12:1935-1939.
18. Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487-498.